Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-06-17 16:45:11 ET · period of report 2026-06-15 · accession 0001470831-26-000550 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-17 16:45 | 2026-06-15 | BBIO | Cook Jennifer E. | Dir | M - OptEx | $10.16 | +83.1K | 96.8K | +605% | +$844.6K |
| DMT | 2026-06-17 16:45 | 2026-06-15 | BBIO | Cook Jennifer E. | Dir | S - Sale+OE | $66.62 | -90.2K | 6,589 | -93% | -$6.01M |
| DMT | 2026-06-17 16:45 | 2026-06-15 | BBIO | Cook Jennifer E. | Dir | M - OptEx | $0.00 | -83.1K | 34.3K | -71% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-15 | M | A | 65,921 | $8.45 | 79,662 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. |
| 2 | Common | Common Stock | 2026-06-15 | M | A | 17,167 | $16.75 | 96,829 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. |
| 3 | Common | Common Stock | 2026-06-15 | S | D | 88,737 | $66.62 | 8,092 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. (F2) Represents the weighted average sale price of the shares sold from $66.10 to $67.095 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-06-15 | S | D | 1,503 | $67.14 | 6,589 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. (F3) Represents the weighted average sale price of the shares sold from $67.10 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-06-15 | M | D | 65,921 | $0.00 | 39,000 | D | $8.45 · — to 2032-06-22 | 65,921 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. (F4) 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-06-15 | M | D | 17,167 | $0.00 | 34,334 | D | $16.75 · — to 2033-06-21 | 17,167 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. (F5) 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. |